If you'd invested $10,000 in Novavax(NASDAQ: NVAX) a year ago, you would have made a risky bet. That's because the biotech company had issued a going concern earlier this year. This warning meant that, if uncertainty persisted, the company might have had to shut down.
Prior to that, Novavax, a star earlier in the pandemic, saw its shares drop more than 90% from their peak. The company's coronavirus vaccine reached the market late and missed out on the biggest revenue opportunities, disappointing investors.
Along with the going concern, Novavax launched a major cost-cutting plan. Considering all of this, how did your $10,000 investment turn out?
Image source: Getty Images.
Novavax's $1.2 billion deal
Novavax has made considerable progress in controlling costs, reducing expenses in the hundreds of millions of dollars last year. But it was news about a partnership that gave the shares a clear direction over just the past few days.
Sanofi signed a $1.2 billion deal with Novavax, giving the pharmaceutical giant rights to co-commercialize Novavax's coronavirus vaccine. As a result, Novavax shares surged.
If you'd invested $10,000 in Novavax a year ago, right now, you'd have $15,200. And here's even better news: The Sanofi agreement could be a game changer for Novavax, so there's reason to be optimistic about the stock over the long term.
Why is the Sanofi deal so important? Sanofi sells the world's leading flu vaccines, so the company has the commercial infrastructure and experience necessary to help Novavax carve out market share in the coronavirus vaccine market.
Sanofi also could be the source of ongoing revenue for Novavax since it licensed the biotech's Matrix-M adjuvant technology for potential use in its products. Finally, Sanofi demonstrated its confidence in Novavax by taking a nearly 5% stake in the company.
All of this could prompt a new wave of growth for Novavax. So if you took a risk last year by buying Novavax, it's paying off -- and the momentum may be just getting started.
Should you invest $1,000 in Novavax right now?
Before you buy stock in Novavax, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novavax wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $559,743!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of May 13, 2024
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
